Norbit100 mg

Norbit is a Class IA antiarrhythmic agent indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, when the potential benefit to the patient outweighs the risk of proarrhythmia. Because of its proarrhythmic potential and negative inotropic effects, Norbit is generally reserved for patients who cannot tolerate or have not responded to other antiarrhythmic therapy.

• Established/FDA-approved use: Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia).
• Guideline-supported adjunct use: Norbit has also been used, in specialist cardiology settings, as an adjunct to reduce left ventricular outflow tract obstruction in selected patients with obstructive hypertrophic cardiomyopathy who cannot take or do not respond to other agents, owing to its negative inotropic effect.
• Not indicated for asymptomatic ventricular premature beats or non-life-threatening arrhythmias, given the risk of proarrhythmia and mortality demonstrated with Class I antiarrhythmics in patients with structural heart disease.

Norbit should be initiated and dose-titrated in a setting where cardiac rhythm can be monitored, typically under specialist supervision.

Each unit dose of Disopyramide Phosphate contains Disopyramide Phosphate as the active pharmaceutical ingredient, available as immediate-release capsules and, in some markets, as extended/controlled-release capsules. Common strengths include 100 mg and 150 mg per capsule. Excipients vary by manufacturer and formulation; refer to the specific product label for the complete excipient list.

Norbit is a Class IA antiarrhythmic drug chemically unrelated to other antiarrhythmic agents. It is the phosphate salt of disopyramide, an orally active agent used to suppress and prevent recurrence of serious ventricular arrhythmias. Norbit shares the sodium-channel-blocking, action-potential-prolonging properties typical of the Class IA group (along with quinidine and procainamide) but also has clinically significant anticholinergic and negative inotropic properties that distinguish its side-effect profile.

Norbit belongs to the Class IA antiarrhythmic group (sodium channel blockers that prolong the cardiac action potential and QT interval).

Mechanism of Action

Disopyramide Phosphate blocks fast inward sodium channels in cardiac cell membranes, reducing the maximum rate of depolarization (phase 0) of the action potential. This slows conduction velocity in atrial, His-Purkinje, and ventricular tissue. Disopyramide Phosphate also prolongs the action potential duration and effective refractory period, which is the hallmark of Class IA agents (an intermediate rate of sodium channel dissociation compared with Class IB and Class IC drugs). At therapeutic concentrations, Disopyramide Phosphate has minimal effect on sinus node automaticity in normal hearts but can suppress ectopic ventricular pacemaker activity.

Additional Pharmacologic Properties

• Anticholinergic activity: Disopyramide Phosphate has significant antimuscarinic effects, which can cause dry mouth, urinary retention, blurred vision, and constipation, and can offset its direct slowing effect on AV nodal conduction.
• Negative inotropic effect: Disopyramide Phosphate reduces myocardial contractility more than other Class IA agents, which can precipitate or worsen heart failure in susceptible patients; this property is used therapeutically in obstructive hypertrophic cardiomyopathy.

Pharmacokinetics

Disopyramide Phosphate is well absorbed orally (bioavailability approximately 80-90%), with peak plasma concentrations reached in about 2 hours (immediate release). It is roughly 50-65% bound to plasma proteins (binding is concentration-dependent and saturable). Disopyramide Phosphate is partly metabolized in the liver to an active metabolite (mono-N-dealkyl disopyramide, which has significant anticholinergic but less antiarrhythmic activity) and is substantially excreted unchanged by the kidneys. The elimination half-life is approximately 4-10 hours in patients with normal renal function and is prolonged in renal impairment.

Norbit capsules should be swallowed whole with water, with or without food. Extended-release capsules must not be crushed, chewed, or split. Doses should be taken at evenly spaced intervals as prescribed to maintain stable blood levels, and initiation/titration should occur under cardiac monitoring.

• QT-prolonging drugs (e.g., other Class IA/III antiarrhythmics, certain macrolides, azole antifungals, some antipsychotics): concurrent use with Norbit increases the risk of additive QT prolongation and torsades de pointes; avoid combination where possible.
• CYP3A4 inhibitors (e.g., erythromycin, clarithromycin, ketoconazole, certain protease inhibitors): can significantly increase Norbit plasma concentrations, raising the risk of cardiotoxicity; avoid or use with intensive monitoring.
• CYP3A4 inducers (e.g., rifampin, phenytoin, phenobarbital): can lower Norbit plasma concentrations and reduce antiarrhythmic efficacy; dose adjustment and monitoring may be needed.
• Other negative inotropes (e.g., beta-blockers, verapamil): concurrent use with Norbit can produce additive negative inotropic effects and precipitate heart failure or hypotension, particularly in patients with hypertrophic cardiomyopathy or underlying left ventricular dysfunction.
• Other anticholinergic drugs: additive antimuscarinic effects (urinary retention, dry mouth, constipation, precipitation of glaucoma) may occur when combined with Norbit.

Common

Anticholinergic effects are the most frequent side effects of Norbit, including dry mouth, constipation, blurred vision, and urinary hesitancy/retention.

Less Common but Clinically Important

• Cardiovascular: hypotension, worsening or new-onset heart failure, conduction disturbances, QT prolongation, and proarrhythmia (including torsades de pointes).
• Metabolic: hypoglycemia (more common in elderly, malnourished, renally impaired, or diabetic patients).
• Ocular: precipitation of angle-closure glaucoma.
• Other: nausea, dizziness, fatigue, elevated liver enzymes (rare cholestatic jaundice).

Patients should seek prompt medical attention for palpitations, fainting, significant swelling, marked reduction in urination, or visual disturbances while taking Norbit.

Pregnancy: Animal reproduction studies have not shown clear teratogenic risk, but adequate, well-controlled studies in pregnant women are lacking. Norbit crosses the placenta and has been reported to have an oxytocic (uterine-stimulating) effect. Norbit should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close physician supervision.

Lactation: Norbit and its active metabolite are excreted into breast milk. Because of the potential for adverse effects in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother; consult a physician before breastfeeding while taking Norbit.

• Heart failure: Norbit has a pronounced negative inotropic effect and can precipitate or worsen heart failure; use with extreme caution, at reduced doses, in patients with pre-existing left ventricular dysfunction, and correct decompensated heart failure before starting therapy where possible.
• Proarrhythmia and QT prolongation: Like other Class IA agents, Norbit can cause new or worsened arrhythmias, including torsades de pointes; correct hypokalemia and hypomagnesemia before and during treatment, and monitor ECG closely, especially during initiation and dose titration.
• Anticholinergic effects: Use with caution in patients with urinary retention or bladder outlet obstruction (e.g., prostatic hypertrophy), narrow-angle glaucoma, and myasthenia gravis, as Norbit can worsen these conditions.
• Hypoglycemia: Norbit has been associated with hypoglycemia, particularly in elderly, malnourished, or renally/hepatically impaired patients, and in those with diabetes on hypoglycemic therapy; monitor blood glucose in at-risk patients.
• Conduction disease: Use with caution in patients with sick sinus syndrome, bundle branch block, or first-degree AV block, as Norbit can worsen conduction abnormalities.
• Renal/hepatic impairment: Requires dose reduction and monitoring due to reduced clearance (see Dosage and Administration).

Overdose with Norbit is a medical emergency and can cause severe cardiotoxicity, including markedly widened QRS complex, hypotension, conduction block, ventricular arrhythmias, and cardiac arrest, as well as pronounced anticholinergic toxicity. If overdose is suspected, seek immediate emergency medical attention or contact a poison control center; continuous ECG and hemodynamic monitoring in a hospital setting are required. There is no specific antidote; management is supportive, guided by treating physicians, and may include measures to support blood pressure and cardiac rhythm.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric use: Safety and efficacy of Norbit have not been formally established in children in well-controlled trials; when used off-label under specialist pediatric cardiology supervision, dosing is individualized and weight-based, with close ECG monitoring.
• Elderly: Use lower initial doses and monitor closely, given the higher prevalence of renal impairment and increased sensitivity to anticholinergic and negative inotropic effects.
• Renal impairment: Requires dose/interval adjustment based on creatinine clearance; see Dosage and Administration.
• Hepatic impairment: Requires dose reduction and monitoring.

Duration of treatment with Norbit is individualized by the treating cardiologist based on arrhythmia control, ECG monitoring, and tolerability; it is often used long-term for recurrence prevention in patients with life-threatening ventricular arrhythmias, with periodic reassessment of continued need and safety.

Class IA Antiarrhythmic (Sodium Channel Blocker)

Disopyramide Phosphate blocks fast sodium channels in cardiac tissue, slowing phase 0 depolarization and conduction velocity while prolonging the action potential duration and effective refractory period; it also exerts significant anticholinergic and negative inotropic effects that shape its clinical use and side-effect profile.

C

Safety and efficacy of Norbit have not been formally established in pediatric patients through well-controlled trials. When used off-label for life-threatening pediatric ventricular arrhythmias, it is administered under specialist pediatric cardiology supervision with individualized, weight-based dosing and close ECG monitoring.